Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

67.00
-0.7400-1.09%
Volume:201.50K
Turnover:13.60M
Market Cap:9.44B
PE:-29.34
High:68.00
Open:67.83
Low:66.66
Close:67.74
52wk High:95.49
52wk Low:29.81
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.66
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:20.27
PE(LYR):-5,494.96

Loading ...

Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Q2 Loss $0.93, vs. FactSet Est of $1.10 Loss

MT Newswires Live
·
May 08

Arrowhead swings to FY26 Q2 net loss of $132.73 million; revenue falls to $73.74 million

Reuters
·
May 08

BRIEF-Arrowhead Pharmaceuticals Q2 EPS USD -0.93

Reuters
·
May 08

Arrowhead Pharmaceuticals Q2 Operating Income USD -141.26 Million

THOMSON REUTERS
·
May 08

Corrected-Arrowhead Pharmaceuticals Q2 Net Income USD -132.7 Million (Corrects Amount)

THOMSON REUTERS
·
May 08

Arrowhead Pharmaceuticals Q2 Operating Expenses USD 214.997 Million

THOMSON REUTERS
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Arrowhead Pharmaceuticals - Madrigal to Pay $25 Mln Upfront and up to $975 Mln in Milestones to Arrowhead

THOMSON REUTERS
·
May 05

Arrowhead Pharmaceuticals - Eligible for Tiered Royalties on Commercial Sales

THOMSON REUTERS
·
May 05

Arrowhead licenses ARO-PNPLA3 MASH drug to Madrigal for USD 25 million upfront

Reuters
·
May 05

Arrowhead Pharmaceuticals to present at BofA Securities 2026 Healthcare Conference

Reuters
·
May 04

Arrowhead Pharmaceuticals Initiated at Overweight by JP Morgan

Dow Jones
·
May 01

Arrowhead says Australia TGA approves REDEMPLO for familial chylomicronemia syndrome

Reuters
·
May 01

Arrowhead Pharmaceuticals Receives Tga Approval of Redemplo® (Plozasiran) in Australia, Expanding Global Access for Patients With Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS
·
May 01

Arrowhead Pharmaceuticals - Phase 3 Study Shows Redemplo Reduces Triglycerides by Median 80% From Baseline

THOMSON REUTERS
·
May 01

JPMorgan Initiates Arrowhead Pharmaceuticals at Overweight With $88 Price Target

MT Newswires Live
·
May 01

Arrowhead Pharmaceuticals : JP Morgan Initiates Coverage With Overweight Rating; Target Price $88

THOMSON REUTERS
·
May 01

Earning Preview: Arrowhead Pharmaceuticals this quarter’s revenue is expected to increase by 153%, and institutional views are bullish

Earnings Agent
·
May 01

Earning Preview: Arrowhead Pharmaceuticals this quarter’s revenue is expected to increase by 153.09%, and institutional views are bullish

Earnings Agent
·
May 01

A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS

Simply Wall St.
·
Apr 28